Unicycive Therapeutics at Guggenheim conference: launch plan takes shape Investing.com · News 20m ago
Accenture vs. Adobe: What Does Fluctuating vs. Steady Revenue Tell Investors? NASDAQ · Markets 23m ago
GE Vernova sellers have it all wrong — plus, why Fed rate hike odds are soaring CNBC · Economy 26m ago
Bank of America's Preferred Stock, Series E Crosses Above 6.5% Yield Territory NASDAQ · Markets 26m ago